Get the Stockscreener App
21.23
2.57%
-0.56
After Hours:
21.23
Nurix Therapeutics Inc stock is traded at $21.23, with a volume of 556.61K.
It is down -2.57% in the last 24 hours and down -19.19% over the past month.
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies. Its drug candidate from E3 ligase inhibitor portfolio, NX-1607, is an orally available CBL-B inhibitor for immuno-oncology indications.
See More
Previous Close:
$21.79
Open:
$21.87
24h Volume:
556.61K
Relative Volume:
0.69
Market Cap:
$1.54B
Revenue:
$80.89M
Net Income/Loss:
$-144.73M
P/E Ratio:
-7.1481
EPS:
-2.97
Net Cash Flow:
$-83.87M
1W Performance:
-6.23%
1M Performance:
-19.19%
6M Performance:
+39.95%
1Y Performance:
+257.41%
1-Day Range:
$21.09
$22.10
1-Week Range:
$21.06
$23.09
52-Week Range:
$5.68
$29.56
Nurix Therapeutics Inc Stock (NRIX) Company Profile
Name
Nurix Therapeutics Inc
Sector
Industry
Phone
(415) 660-5320
Address
1700 OWENS STREET, SUITE 205, SAN FRANCISCO
Compare NRIX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NRIX
Nurix Therapeutics Inc
|
21.23 | 1.54B | 80.89M | -144.73M | -83.87M | -2.97 |
|
VRTX
Vertex Pharmaceuticals Inc
|
464.56 | 119.70B | 10.63B | -479.80M | -1.35B | 13.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
754.87 | 82.75B | 13.85B | 4.65B | 3.32B | 35.06 |
|
ARGX
Argen X Se Adr
|
614.59 | 36.73B | 1.86B | -40.29M | -1.28B | -4.16 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.74 | 32.53B | 2.09B | -332.26M | 16.06M | -4.14 |
|
BNTX
Biontech Se Adr
|
120.72 | 28.50B | 3.30B | -501.07M | 1.03B | 11.54 |
Nurix Therapeutics Inc Stock (NRIX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-24-24 | Initiated | UBS | Buy |
| Oct-11-24 | Initiated | Jefferies | Buy |
| Sep-06-24 | Resumed | Robert W. Baird | Outperform |
| Jul-31-24 | Initiated | Truist | Buy |
| Jun-26-23 | Resumed | Oppenheimer | Outperform |
| Mar-09-23 | Initiated | Barclays | Overweight |
| Feb-28-23 | Initiated | Oppenheimer | Outperform |
| Oct-11-22 | Initiated | Morgan Stanley | Equal-Weight |
| May-31-22 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Feb-10-22 | Initiated | Wells Fargo | Equal Weight |
| Dec-29-21 | Initiated | H.C. Wainwright | Buy |
| Oct-14-21 | Initiated | SVB Leerink | Outperform |
| Jun-04-21 | Resumed | Robert W. Baird | Outperform |
| Apr-30-21 | Resumed | Piper Sandler | Overweight |
| Apr-30-21 | Initiated | RBC Capital Mkts | Outperform |
| Apr-14-21 | Initiated | Berenberg | Buy |
| Nov-19-20 | Initiated | Robert W. Baird | Outperform |
| Aug-18-20 | Initiated | JP Morgan | Overweight |
| Aug-18-20 | Initiated | Needham | Buy |
| Aug-18-20 | Initiated | Piper Sandler | Overweight |
| Aug-18-20 | Initiated | Stifel | Buy |
View All
Nurix Therapeutics Inc Stock (NRIX) Latest News
Nurix Therapeutics CEO to Present at Piper Sandler Healthcare Conference | NRIX Stock News - StockTitan
Nurix Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference - GlobeNewswire
(NRIX) Proactive Strategies - Stock Traders Daily
GSA Capital Partners LLP Sells 15,134 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) - Defense World
Nurix Therapeutics, Inc. (NASDAQ:NRIX) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Nurix Therapeutics, Inc. (NASDAQ:NRIX) Receives Average Rating of “Moderate Buy” from Analysts - Defense World
Nurix Therapeutics Receives PRIME Designation from the European Medicines Agency for NX-5948 for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia - The Manila Times
Nurix gains EMA prime status for leukemia drug candidate - Investing.com
Nurix Therapeutics Receives PRIME Designation from the - GlobeNewswire
Nurix's Cancer Drug NX-5948 Secures EMA PRIME Status for Advanced Leukemia Treatment | NRIX Stock News - StockTitan
Amalgamated Bank Has $49,000 Stock Position in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - Defense World
Nurix Therapeutics (NASDAQ:NRIX) Shares Gap DownShould You Sell? - MarketBeat
Sumitomo Mitsui Trust Group Inc. Purchases New Shares in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
Chevron Corp (CVX-N) QuotePress Release - The Globe and Mail
Mplx LP (MPLX-N) QuotePress Release - The Globe and Mail
Nurix Therapeutics Presents Preclinical Data from Two Autoimmune and Inflammatory Disease Programs, NX-5948 and GS-6791, at ACR Convergence 2024 - The Manila Times
Nurix Therapeutics Presents Preclinical Data from Two - GlobeNewswire
Nurix Reports Strong Preclinical Data for Two Novel Autoimmune Disease Treatments | NRIX Stock News - StockTitan
Nurix Therapeutics (NASDAQ:NRIX) Shares Down 8.7%Should You Sell? - MarketBeat
Redmile Group, LLC Expands Stake in Nurix Therapeutics Inc - GuruFocus.com
Significant Stake Increase by Baker Bros. Advisors in Nurix Ther - GuruFocus.com
WASATCH ADVISORS LP Adjusts Stake in Nurix Therapeutics Inc - GuruFocus.com
When the Price of (NRIX) Talks, People Listen - Stock Traders Daily
Conocophillips (COP-N) QuotePress Release - The Globe and Mail
Wellington Management Group LLP Increases Stake in Nurix Therape - GuruFocus.com
Nurix Therapeutics, Inc. (NASDAQ:NRIX) Shares Purchased by International Assets Investment Management LLC - Defense World
ARK Investment Management LLC Has $49.80 Million Position in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
Morgan Stanley's Strategic Reduction in Nurix Therapeutics Holdi - GuruFocus.com
Nurix Therapeutics stock soars to 52-week high of $27.61 By Investing.com - Investing.com Canada
Nurix Therapeutics (NASDAQ:NRIX) Hits New 1-Year HighHere's Why - MarketBeat
Nurix Therapeutics stock soars to 52-week high of $27.61 - Investing.com India
Subdued Growth No Barrier To Nurix Therapeutics, Inc. (NASDAQ:NRIX) With Shares Advancing 25% - Simply Wall St
The Analyst Verdict: Nurix Therapeutics In The Eyes Of 10 Experts - Benzinga
Nurix Therapeutics' (NRIX) "Buy" Rating Reiterated at Needham & Company LLC - MarketBeat
Nurix Therapeutics Announces Presentations at the 66th American Society of Hematology (ASH) Annual Meeting - GlobeNewswire
Nurix therapeutics' chief legal officer sells $82,250 in stock - Investing.com India
SEC Form 424B5 filed by Nurix Therapeutics Inc. - Quantisnow
Nurix therapeutics' chief legal officer sells $82,250 in stock By Investing.com - Investing.com UK
(NRIX) Technical Pivots with Risk Controls - Stock Traders Daily
Nurix therapeutics CFO Hans van Houte sells $86,083 in stock - Investing.com India
Houte Hans Van Sells 3,546 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) Stock - MarketBeat
Nurix therapeutics CFO Hans van Houte sells $86,083 in stock By Investing.com - Investing.com Australia
Nurix therapeutics chief legal officer sells $139,866 in stock By Investing.com - Investing.com South Africa
Nurix therapeutics chief legal officer sells $139,866 in stock - Investing.com India
Insider Sale: CFO Houte Van Sells Shares of Nurix Therapeutics I - GuruFocus.com
Nurix Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewswire
Companies Like Nurix Therapeutics (NASDAQ:NRIX) Are In A Position To Invest In Growth - Simply Wall St
Nurix therapeutics chief scientific officer sells shares worth $83,536 By Investing.com - Investing.com Australia
Nurix therapeutics chief legal officer sells shares worth over $101k By Investing.com - Investing.com South Africa
Nurix therapeutics chief scientific officer sells shares worth $83,536 - Investing.com
Nurix therapeutics chief legal officer sells shares worth over $101k - Investing.com
Nurix Therapeutics Inc Stock (NRIX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Nurix Therapeutics Inc Stock (NRIX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Ring Christine | Chief Legal Officer |
Nov 04 '24 |
Sale |
25.00 |
3,290 |
82,250 |
28,084 |
1.35%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):